Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.47
-0.0900-5.77%
Post-market: 1.46-0.0100-0.68%19:58 EDT
Volume:2.97M
Turnover:4.25M
Market Cap:121.98M
PE:-0.51
High:1.58
Open:1.57
Low:1.36
Close:1.56
Loading ...

Editas Medicine: Expects Existing Cash, Cash Equivalents, Marketable Securities to Fund Oper Expenses & Capex Into Q2 2026

THOMSON REUTERS
·
04 Nov 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

THOMSON REUTERS
·
04 Nov 2024

Editas Medicine Inc: Qtrly Loss per Shr $0.75

THOMSON REUTERS
·
04 Nov 2024

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

GlobeNewswire
·
04 Nov 2024

Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?

Insider Monkey
·
31 Oct 2024

Editas Medicine Inc expected to post a loss of 75 cents a share - Earnings Preview

Reuters
·
30 Oct 2024

Analysts Estimate Adherex Technologies Inc. (FENC) to Report a Decline in Earnings: What to Look Out for

Zacks
·
28 Oct 2024

Earnings Preview: Editas Medicine (EDIT) Q3 Earnings Expected to Decline

Zacks
·
25 Oct 2024

Editas Medicine: Strategic Shift Towards In Vivo Technologies and Long-term Growth Potential

TIPRANKS
·
25 Oct 2024

Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More

Zacks
·
24 Oct 2024

Editas Medicine: Balancing Strategic Shifts and Uncertainties with a Hold Rating

TIPRANKS
·
24 Oct 2024

EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down

Zacks
·
23 Oct 2024

Evercore ISI Reaffirms Their Hold Rating on Editas Medicine (EDIT)

TIPRANKS
·
23 Oct 2024

Editas Medicine (EDIT) Gets a Hold from Oppenheimer

TIPRANKS
·
23 Oct 2024

Strategic Shift and Promising Data Boost Buy Rating for Editas Medicine

TIPRANKS
·
23 Oct 2024

Cautious Hold on Editas Medicine Amid Strategic Shifts and Financial Uncertainties

TIPRANKS
·
23 Oct 2024